Zeneca Sponsors Rural Breast Cancer Outreach

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 11
Volume 6
Issue 11

CHICAGO-October’s National Breast Cancer Awareness Month (NBCAM) had a special focus on women in America’s agricultural communities. Zeneca, a founding co-sponsor of NBCAM, said that its breast cancer education program will target rural women to raise awareness of the need for mam-mography and other early detection methods in this population.

CHICAGO—October’s National Breast Cancer Awareness Month (NBCAM) had a special focus on women in America’s agricultural communities. Zeneca, a founding co-sponsor of NBCAM, said that its breast cancer education program will target rural women to raise awareness of the need for mam-mography and other early detection methods in this population.

Bob Woods, president of Zeneca Ag Products, made the announcement from the Chicago Board of Trade where he rang the opening bell in a symbolic call to action.

The centerpiece of the rural outreach effort is a Program Leaders Workshop where women with ties to agribusiness communities will be trained to be “ambassadors” of breast cancer awareness. For more information, see the NBCAM Home Page at http://www.nbcam.org.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content